Unlock the power of repurposed drugs
Through our Rare Treatment Accelerator (RTA) programme, we partner with academic groups, patient organisations and early-stage biotechs who have identified promising drug repurposing opportunities for rare diseases but who need additional financial and clinical resources to take these all the way to patients.
By applying our AI technology, drug development and clinical expertise, along with the necessary financial resources, we will evaluate, enhance and accelerate the development of your repurposed drugs – with the aim of starting a clinical trial within 6-12 months from project start.
We’re particularly keen to hear about projects where there is good evidence that the repurposed drug has therapeutic effects in preclinical disease models and is suitable to move towards human clinical trials.
And whilst we’re very interested in diseases that fit with our current portfolio, we also welcome applications from groups working on other rare conditions where relevant assets, resources and data are available to allow us to fast-track projects to the clinic.